Trials / Completed
CompletedNCT02359058
A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer
Phase 1b Study of Ramucirumab in Combination With Fluoropyrimidines and Platinum-Based Agents in Japanese Patients With Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and antitumor response of ramucirumab in combination with platinum/fluoropyrimidine regimens in Japanese participants with advanced gastric/gastrooesophageal junction cancer who have not received chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ramucirumab | Administered IV |
| DRUG | Capecitabine | Administered orally |
| DRUG | Cisplatin | Administered IV |
| DRUG | S-1 | Administered orally |
| DRUG | Oxaliplatin | Administered IV |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2016-07-01
- Completion
- 2016-11-01
- First posted
- 2015-02-09
- Last updated
- 2018-01-24
- Results posted
- 2017-12-04
Locations
4 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02359058. Inclusion in this directory is not an endorsement.